Clinical-stage immunotherapy company Nantkwest Inc NK reports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday.
What Happened: Nantkwest said that early interim results of its PD-L1 t-haNK protocols showing median survival rates more than doubled that of the historical rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists.
The data validates the theory that survival rates could be improved without high-dose chemotherapy by orchestrating natural killer and T-cell therapy.
The trials were based on the original Cancer Moonshot hypothesis, a collaborative trial involving the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including Nantkwest, ImmunityBio, Bristol-Myers Squibb Co BMY-owned Celgene, and Pfizer Inc. PFE.
Interim Study Results: Moonshot QUILT trials of haNK combined with PD-L1 inhibitor avelumab were completed in 2019, showed that the median overall survival rate more than doubled in the 12-patient study compared to historical controls. Details here.
Four out of five patients who had not yet reached median survival time (three months) are alive 8-16 months since beginning treatment on these expanded protocols when replacing haNK and PD-L1 inhibitor avelumab with PD-L1 t-haNK.
A single-arm Phase 2 QUILT 88 study was initiated in October 2020, the primary endpoint for which is overall survival, and 15 out of 18 (83%) of patients enrolled with second-line or greater pancreatic cancer remain alive to date.
A randomized Phase 2 QUILT 88 study for first- and second-line metastatic pancreatic cancer is actively enrolling at three sites.
Why It Matters: "These observations confirmed the promise of our hypothesis that activating the patient's own immune system with low-dose chemo immunomodulation therapy could improve outcomes," said Patrick Soon-Shiong, M.D., Chairman, and CEO of ImmunityBio.
The data is still early but warrants further confirmation of doubling the survival rate through QUILT 88, Soon-Shiong added.
In December 2020, Nantkwest had a reverse-merger deal with privately-held ImmunityBio. The combined company is expected to close the transaction by the first quarter of 2021 and list under the ticker symbol 'IBRX' on Nasdaq.
Price Action: NK shares are trading higher by 19.1% at $17.60 in the pre-market session on the last check Thursday.
Related News: Cramer Shares His Thoughts On AT&T, Nantkwest And More
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
